Loading…
← CockpitCompetitor Analysis › 688617.SS APT Medical Inc. Class AOpen in the cockpit ↗

APT Medical Inc. Class A688617.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese maker of cardiac electrophysiology catheters and cardiovascular devices used to treat heart arrhythmias.

≈ A Chinese Abbott Electrophysiology/Boston Scientific (EP devices)Momentum leader 99
Mkt cap
$6.06B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$73.3M
20-day average traded
Fwd P/E
38.6×
forward earnings
ROIC−WACC
+49.8 pp
WACC 5.0%
Hurdle
-31 pp
Req g minus delivered
Next earnings
132 days
30 Mar 2027
Close · CNYCN¥288.00
1D-1.6%
1W+3.4%
1M+14.1%
3M+32.4%
6M+23.0%
YTD+18.4%
1Y+4.6%
ATR %3.8%
52w lowhigh2.2% off high

What APT Medical does

Chinese maker of cardiac electrophysiology catheters and cardiovascular devices used to treat heart arrhythmias.

In one line: A Chinese Abbott Electrophysiology/Boston Scientific (EP devices).

Products and services

  • EP catheters/mapping systems
  • Coronary/peripheral vascular devices
  • Vascular access products

Customers

  • Cardiologists/hospitals

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Cardiac electrophysiology & vascular…

What could go right

  • China electrophysiology procedure-volume growth
  • Import substitution

What could go wrong

  • Government volume-based procurement price cuts

Moat: narrow (IP / patents, regulatory licence). Device approvals and physician training create switching costs once a device is adopted.

Headquarters: Shenzhen, Guangdong, China · Employees: 3,118

Named competitors

APT Medical at a glance

Size APT Medical (688617.SS) is a China Health Care company (Medical Specialties) with a market value of $6.06B, the 386th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥288.00 on 18 Nov 2026.

Performance Over six months the shares gained 23.0%, against +30.8% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 28.0% over the last twelve months (peer median +6.8%); the operating margin is 36.6% (peer median 14.5%).

Valuation It trades at 38.6× forward earnings against a peer median of 20.7× (most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -31 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 49.8 points above its cost of capital (5.0% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 131688617.SS 127
Six months, rebased to 100: APT Medical against the median of its 20 peers (local-currency closes).

APT Medical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.07BCN¥2.56BCN¥2.04BCN¥1.63BCN¥1.20B
Revenue growth—+25%+25%+36%—
Gross profitCN¥2.29BCN¥1.79BCN¥1.42BCN¥1.12BCN¥824M
EBITDAn/aCN¥995MCN¥797MCN¥588MCN¥416M
Net incomeCN¥1.02BCN¥821MCN¥673MCN¥534MCN¥358M
Free cash flowCN¥1.07BCN¥690MCN¥101MCN¥507MCN¥272M
Capital expenditureCN¥179MCN¥286MCN¥650MCN¥202MCN¥143M
Total debtCN¥12.0MCN¥19.4MCN¥11.3MCN¥89.9MCN¥52.6M

Quarterly statements and history in the cockpit →

APT Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+20%HAETFXLNTHCOHCTECYPSNLIVN7747MMSIBLCOGETI-B300832300677DIAMMEDSHCGRAL68697701ICUI688617.SS6-month return →1-month return →
Up and to the right = strong over both horizons. APT Medical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%20×30×40×HAETFXLNTHCOHCTECYPSNLIVN7747MMSIBLCOGETI-B300832300677MMEDSHC6869ICUI688617.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. APT Medical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%HAETFXLNTHCOHCTECLIVN7747MMSIGETI-B300832300677DIA6869ICUI688617.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. APT Medical is the large dot.

APT Medical competitors and peer comparison

Head to head with its named competitors (688617.SS vs ABT vs BSX vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
APT Medical 688617.SS$6.06B+23%+28%37%38.6×9.0%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
MicroPort Scientific 0853.HKn/a-45%n/an/an/an/a

How APT Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

APT Medical against its 20 peers (data as of 18 Nov 2026)
Measure688617.SSPeer medianRank in peer set
1-month return+14.1%+10.3%9th highest of 21
6-month return+23.0%+30.8%6th lowest of 21
Distance from 52-week high-2.2%-7.2%6th highest of 21
Revenue growth (TTM)+28.0%+6.8%2nd highest of 21
Operating margin36.6%14.5%3rd highest of 21
Forward P/E38.6×20.7×most expensive of 20
Growth the price implies (Req g, 7 yrs)9.0%12.0%8th least demanding of 18
Growth delivered (Del g)+40.1%+8.9%highest of 18
Hurdle (Req g minus delivered)-31.1 pp+2.0 pp2nd least demanding of 18
ROIC minus cost of capital+49.8 pp+2.5 pphighest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
Teleflex TFXUnited States$6.58B+23%-29%12%16.7×16.5%-4.7%
Lantheus LNTHUnited States$6.67B+6%+2%19%15.5×0.4%+35.3%
Cochlear COH.AXAustralia$6.72B+58%-1%13%29.1×23.9%+9.3%
ConvaTec CTEC.LUnited Kingdom$6.78B+37%+2%16%17.7×17.2%+4.6%
Ypsomed YPSN.SWSwitzerland$6.83B+27%-13%30%31.7×n/an/a
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
GRAIL GRALUnited States$4.59B+67%+17%-332%n/an/an/a
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
ICU Medical ICUIUnited States$4.46B+38%-6%8%19.4×18.9%+11.9%

Questions

Who are APT Medical's main competitors?
Named competitors: Abbott Laboratories (ABT), Boston Scientific (BSX), Johnson & Johnson (Biosense Webster) (JNJ), MicroPort Cardiac (0853.HK). The cockpit's measured peer set (industry) also includes Haemonetics (HAE), Teleflex (TFX), Lantheus (LNTH), Cochlear (COH.AX), ConvaTec (CTEC.L), Ypsomed (YPSN.SW).
Is APT Medical expensive compared with its peers?
On forward p/e it trades at 38.6× against a peer median of 20.7×, most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -31 pp: the price already allows for a slowdown.
How has APT Medical stock performed?
Over six months to 18 Nov 2026 the shares returned +23.0% against +30.8% for the median peer; over one year +4.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.